11
April 2022
New Data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors Presented at AACR 2022
the ORR was 55.0%, the DCR was 85.0%, the 6-month PFS rate was 84.1%; Out of 11 evaluable CRC patients, the ORR and DCR was 45.5% and 90.9% respectively.